KCNK17 was further proposed as a genetic modifier of long QT syndrome type 2 severity, as a common KCNK17 gain-of-function variant was shown to be LQTS protective by promoting APD shortening [74]. This evidence concerns the gene KCNK17 and familial long QT syndrome.